Is Hair Shedding Normal After Starting Treatment? The Clinical Timeline Explained.

The single most common reason patients abandon effective hair loss treatment is increased shedding in the first six to twelve weeks of finasteride or minoxidil use. They interpret this shedding as evidence the medication is not working — or worse, that it is accelerating their loss. The clinical reality is the opposite. Increased shedding in the early weeks of treatment is, in most cases, evidence that the medication is doing exactly what it is supposed to do. Understanding the biology behind this phase is what keeps patients on protocol long enough to reach the results they started treatment to achieve. At Avendano Health, our CLIA-certified lab in Boca Raton (Facility ID: #10D2328758) provides the baseline and monitoring panels that give your treatment clinical grounding from day one. Transparent Cash-Pay Pricing. No Insurance Required. No Hidden Fees.

Get your baseline hair loss labs before starting treatment. View our lab menu here.

The Biology of the Treatment-Induced Shedding Phase

To understand why shedding increases after starting minoxidil, it is necessary to understand what was happening before treatment began. In progressive androgenetic alopecia, a significant proportion of affected follicles enter an abnormally prolonged telogen (resting) phase. These follicles are not actively growing — they are resting, producing no hair shaft, waiting for a growth signal that DHT suppression has attenuated. They are not visible as shedding because they are not actively cycling; they are simply stalled.

When minoxidil is introduced, it signals follicle re-entry into the anagen (growth) phase. But to begin a new anagen cycle, a follicle must first complete its telogen phase and shed the existing club hair — the old resting hair retained in the follicle during the extended telogen period. This synchronized re-entry of multiple follicles into anagen produces the characteristic treatment-induced shedding: a temporary, diffuse increase in shedding as old resting hairs are displaced by newly initiated anagen cycles.

Finasteride contributes to the initial shedding phase through a different mechanism. As scalp DHT is reduced, follicles that were in DHT-driven miniaturization begin to shift into healthier growth cycles — a transition that also involves shedding the hair shafts produced under DHT suppression before the new, healthier cycle begins.

The Clinical Timeline — What to Expect at Each Stage

Weeks 1 to 3: Most patients experience no perceptible change in shedding. The medication is achieving its target biochemical effect — DHT suppression for finasteride, follicular activation for minoxidil — but the hair cycle has not yet reflected this at the scalp surface. This is the period of invisible efficacy.

Weeks 4 to 8: The shedding phase begins for most patients. Daily shed count may increase to one and a half to three times the individual's baseline — typically 100 to 300 hairs per day versus a normal baseline of 50 to 100. The shed hairs are typically short, fine, and telogen club hairs — the old resting hairs being displaced by initiating anagen cycles. This is the highest-risk period for treatment abandonment. Patients who stop treatment here reverse the biological progress that has occurred and reset the treatment timeline if they restart.

Weeks 8 to 12: The shedding phase typically peaks and begins to plateau. The cohort of follicles triggered into anagen by minoxidil have completed their telogen clearing phase. New anagen hair shafts are emerging but are too short to be visible as density improvement yet. This is the most psychologically challenging period of the treatment timeline.

Weeks 12 to 16: Shedding returns toward baseline as the synchronized anagen re-entry cohort is complete. The first signs of new growth — fine, short hairs emerging from previously resting follicles — may be visible under direct light at the scalp surface. Daily shed count normalizes.

Months 4 to 6: New anagen hairs have grown sufficient length to contribute to visible density. Most patients see the first perceptible density improvement in this window. Shedding is at or below pre-treatment baseline. The biological investment of the preceding months becomes visible.

Months 6 to 12: Continued density improvement as multiple anagen cohorts complete their cycles at full, healthy length. Clinical assessment of treatment response is most meaningful at twelve months, when the full impact of sustained DHT suppression and follicular activation can be objectively evaluated.

When Shedding Is Not Normal — The Red Flags

Not all increased shedding during hair loss treatment is the expected treatment-induced phase. The following patterns warrant clinical re-evaluation and updated bloodwork from our General Lab Work menu:

• Shedding that does not begin to decline by week 14 to 16
• Patchy or asymmetrical shedding rather than diffuse loss
• Scalp inflammation, pain, or visible irritation accompanying shedding
• Active shedding persisting beyond four months without any new growth visible
• Shedding continuing at increased levels through month six

These patterns may indicate a concurrent correctable condition — hypothyroidism, iron deficiency, vitamin D deficiency, or alopecia areata — that is driving shedding independently of the androgenetic process and will not respond to finasteride and minoxidil alone. Updated TSH, Ferritin, and Vitamin D testing at month four provides the clinical data to distinguish persistent treatment-induced shedding from a concurrent unaddressed driver.

What to Do During the Shedding Phase

The most clinically important action during the shedding phase is to continue treatment consistently. Missing doses resets the biochemical consistency required for both finasteride's DHT suppression and minoxidil's follicular activation signal. Increasing doses does not accelerate recovery and carries side effect risk. Switching medications restarts the biological timeline.

Monthly standardized photographs under consistent lighting provide objective documentation of change that daily mirror observation cannot. Most patients who believe their treatment is failing during the shedding phase discover on photographic comparison that density at month four is meaningfully better than at baseline — they simply could not perceive slow positive change in real time.

Frequently Asked Questions

How much increased shedding is normal after starting minoxidil?

An increase of 1.5 to 3 times your baseline daily shed count is within the expected range during the treatment-induced shedding phase. If you normally shed approximately 75 hairs per day, shedding of 100 to 200 per day during weeks four to twelve is within the normal clinical range for this phase.

Does finasteride also cause increased shedding?

Finasteride can produce a mild initial shedding phase as follicles transitioning from DHT-driven miniaturization enter healthier growth cycles. This is typically less dramatic than the minoxidil-induced shedding phase and resolves within a similar timeframe.

What if my shedding has not decreased at month four?

Updated bloodwork — TSH, Ferritin, Vitamin D, and Full Blood Count — is the appropriate clinical next step. Persistent shedding beyond the expected window suggests a concurrent driver that the current protocol is not addressing. Available at Avendano Health with results in 24 to 48 hours, no referral required.

Does the shedding phase happen every time I restart treatment after stopping?

Yes. Restarting minoxidil after a period of discontinuation typically produces a new shedding phase as follicles re-enter anagen cycles. This is an additional clinical reason to maintain consistent treatment rather than cycling on and off.